INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...

Hard on the heels of its next-gen migraine competitors, Eli Lilly’s Emgality has been looking for a turbo boost. Solid data in preventing migraines as a follow-up treatment could do the trick. In ...

Please provide your email address to receive an email when new articles are posted on . PHILADELPHIA — Emgality, an FDA-approved treatment for preventing migraines, was effective in chronic and ...

Eli Lilly is facing off against Amgen, Teva and Lundbeck in the competitive field of CGRP migraine prevention drugs, and the drugmaker is now touting data showing its Emgality can reduce total pain ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.

Teva said Lilly migraine drug infringes its patents on rival drug Court finds Lilly failed to prove that patents lacked valid written description (Reuters) - A Boston federal judge on Monday rejected ...